Takeda Reports Positive Phase 3 Results for Zasocitinib in Plaque Psoriasis Takeda Pharmaceutical has announced positive results from its pivotal Phase 3 LATITUDE PsO 3001 and 3002 clinical trials, establishing its selective TYK2 inhibitor, zasocitinib, as a high-efficacy oral candidate for moderate-to-severe plaque psoriasis. With approximately 70 percent of participants achieving a static Physician Global Assessment (sPGA) score of clear or almost clear by the 16-week mark,

Eli Lilly and Company has announced a definitive agreement to acquire clinical-stage biopharmaceutical firm AtaiBeckley in a transaction valued at up to $3.8 billion. The acquisition aims to significantly expand Lilly’s neuroscience pipeline by integrating advanced neuroplastogen therapies designed to treat complex and treatment-resistant mental health conditions. Key Regulatory Proposals The financial terms of the agreement include an initial $2.8 billion upfront cash paymen